Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Abbott Laboratories Announces CE Mark For Coronary Drug Eluting Stent


Tuesday, 21 May 2013 08:00am EDT 

Abbott Laboratories announced CE Mark in Europe for the XIENCE Xpedition 48 Everolimus Eluting Coronary Stent System, the first-of-its-kind treatment for long blockages in the vessels that supply blood to the heart due to coronary artery disease (CAD). XIENCE Xpedition 48 leverages the design and clinical outcomes of the XIENCE family of drug eluting stents in a 48 mm length. Abbott continues to offer physicians more options for the treatment of patients with complex coronary artery disease and is the only manufacturer to offer a coronary drug eluting stent greater than 38 mm in length. XIENCE Xpedition 48 is the latest in a long history of stent innovations pioneered by Abbott, which was the first company to offer physicians size-specific metallic stents for use in small and large vessels of the heart. Studies indicate that physicians choose to use multiple shorter length stents to meet the challenges of treating long blockages - or lesions - in as many as 30% of interventional heart procedures, as conventional stent sizes may not always fully cover the lesion.